Brickell Biotech, Inc.

Welcome everyone to the breakout biotech second quarter 2022 financial results conference call. At this time, all participants are in a listen-only mode. Following some prepared remarks from the company, we will open up the call to Q&A. As a reminder, this conference call is being recorded. I would now like to turn the call over to Garth Russell from Life Science Advisors. Garth?

Thank you, Operator, and good afternoon, everyone. Joining me on today's call are Brickville's Chief Executive Officer, Rob Brown, President and Chief Operating Officer, Andy Scholar, Chief Financial Officer, Bert Marcio, Chief Medical Officer, Dr. Monica Lucchi, and Chief R&D Officer, Deepak Chadha. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We will not undertake obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and other periodic reports on Form 10-Q and 8-K filed with the SEC. It is now my pleasure to turn the call over to the company's Chief Executive Officer, Rob Brown. Rob, the floor is yours.

Thanks, Garth. Good afternoon, everyone, and thanks for joining our call today. This is an exciting time for us as a company as we continue to advance our development pipeline of cutting-edge autoimmune and inflammatory therapies. This is highlighted by BBI-02, our potent first-in-class DERK1A inhibitor, BBI-10, a novel sting inhibitor, and our platform of next-generation kinase inhibitors. These programs now define our company as we strive to transform patients' lives by developing innovative therapeutics and generate value for our shareholders. During the second quarter, we initiated and announced dosing of the first patient in a Phase I study of our lead DERK1A inhibitor program, BBI-02. Advancement of BBI-02 into the clinic is a significant milestone for both our company and this novel target, as it marks the first time a DERK1A inhibitor intended for patients with autoimmune diseases has been orally administrated in humans. We are pleased with the progress in this study thus far and remain on track to report sad and mad top-line results by early 2023. In addition, preclinical development activities are underway for BBI-10, our lead sting inhibitor candidate that we acquired earlier this year. Finally, I'd like to briefly touch on soft-running bromide, or SB for short, for the treatment of primary axillary hyperhidrosis, which we sold to Botanics this past May. Botanics recently publicly stated that it plans to submit the NDA for SB gel 15% to the FDA in the third quarter of 2022. This is of course relevant to BRICL as we are eligible to receive various regulatory and sales milestone payments, as well as tiered earn out payments ranging from high single digits to midteen digits on net sales of Sophrony and Bromide gel. We look forward to sharing any additional updates regarding this program as they become available. Now I'll pass it over to Monica to provide an update on our ongoing pipeline development activities. Monica?